Want to see CLDI full AI Analyst Report?
Top Page
Calidi Biotherapeutics
(CLDI)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.64
▼(-51.07% Downside)
Action:Reiterated
Date:10/20/26
The score is held down primarily by weak financial performance (minimal revenue, persistent losses, and ongoing cash burn) and bearish technicals (below major moving averages with negative MACD). Corporate events add risk via an exchange compliance notice, while valuation provides limited support due to negative earnings and no dividend data.
Positive Factors
Pipeline and Regulatory Progress
Positive FDA feedback on CMC, non-clinical plans, and trial design reduces uncertainty around CLD-401’s development path. Progress toward first-in-human testing could strengthen the platform’s strategic value and create durable clinical catalysts if execution continues.
Negative Factors
Pre-Commercial Revenue Profile
Calidi has not yet established meaningful product revenue, leaving its financial model dependent on successful development, regulatory progress, and future financing. Persistent losses mean the business lacks internally generated earnings to fund research and absorb setbacks over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline and Regulatory Progress
Positive FDA feedback on CMC, non-clinical plans, and trial design reduces uncertainty around CLD-401’s development path. Progress toward first-in-human testing could strengthen the platform’s strategic value and create durable clinical catalysts if execution continues.
Read all positive factors
Calidi Biotherapeutics (CLDI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.47M
Dividend YieldN/A
Average Volume (3M)169.27K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue GrowthN/A
EPS Growth53.95%
CountryUS
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-54.14
Shares Outstanding3,676,474
10 Day Avg. Volume54,437
30 Day Avg. Volume169,268
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.53
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-88.32
Revenue Forecast (FY)N/A
Calidi Biotherapeutics Business Overview & Revenue Model
Company Description
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (d...
How the Company Makes Money
Calidi Biotherapeutics is a clinical-stage biopharmaceutical company and, as such, it generally does not generate meaningful recurring revenue from product sales until a therapy is approved and commercialized. Specific, company-reported revenue br...
Calidi Biotherapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 45.00K | 449.00K |
| Gross Profit | -426.00K | -1.65M | 0.00 | -1.26M | -229.00K | 355.00K |
| EBITDA | -15.62M | -18.19M | -19.73M | -24.20M | -25.00M | -9.45M |
| Net Income | -17.47M | -19.91M | -22.14M | -29.22M | -25.43M | -10.93M |
Balance Sheet | ||||||
| Total Assets | 7.20M | 8.86M | 14.18M | 10.02M | 2.60M | 3.39M |
| Cash, Cash Equivalents and Short-Term Investments | 4.07M | 5.60M | 9.59M | 2.05M | 372.00K | 2.14M |
| Total Debt | 1.94M | 2.56M | 7.04M | 7.24M | 5.99M | 5.18M |
| Total Liabilities | 4.07M | 5.10M | 12.21M | 18.25M | 53.04M | 26.00M |
| Stockholders Equity | 3.13M | 3.76M | 1.53M | -8.23M | -50.44M | -22.61M |
Cash Flow | ||||||
| Free Cash Flow | -17.81M | -21.41M | -19.71M | -27.57M | -13.64M | -7.98M |
| Operating Cash Flow | -17.75M | -21.29M | -19.69M | -26.98M | -13.21M | -7.77M |
| Investing Cash Flow | -144.00K | -170.00K | -16.00K | -478.00K | -494.00K | -215.00K |
| Financing Cash Flow | 16.81M | 17.46M | 27.36M | 29.04M | 12.09M | 9.81M |
Calidi Biotherapeutics Technical Analysis
Negative
1.31
Price Trends
1.08
Negative
1.57
Negative
4.52
Negative
Market Momentum
-0.13
Positive
24.97
Positive
22.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDI, the sentiment is Negative. The current price of 1.31 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 1.08, and below the 200-day MA of 4.52, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 24.97 is Positive, neither overbought nor oversold. The STOCH value of 22.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLDI.
Calidi Biotherapeutics Risk Analysis
Calidi Biotherapeutics disclosed 85 risk factors in its most recent earnings report. Calidi Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Calidi Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
CLDI
Calidi Biotherapeutics
0.67
-24.61
-97.35%
JAGX
Jaguar Animal Health
2.04
-749.84
-99.73%
ADIL
Adial Pharmaceuticals
4.88
-4.04
-45.27%
CDIO
Cardio Diagnostics Holdings
1.75
-2.44
-58.23%
Calidi Biotherapeutics Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Calidi Biotherapeutics Addresses NYSE American Compliance Notice
Negative
Sep 25, 2026
On September 21, 2026, Calidi Biotherapeutics received a notification from NYSE American that it was no longer in compliance with the exchange’s continued listing standard requiring at least $4.0 million in stockholders’ equity for com...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Calidi Biotherapeutics Announces Registered Direct Stock Offering
Positive
Sep 22, 2026
On September 17, 2026, Calidi Biotherapeutics, Inc. entered into a stock purchase agreement with accredited investors and qualified institutional buyers for a registered direct offering of 1,025,640 shares of common stock at $1.17 per share. The o...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresRegulatory Filings and Compliance
Calidi Biotherapeutics Reports Quarterly Results and Pipeline Progress
Positive
Aug 13, 2026
On August 13, 2026, Calidi Biotherapeutics reported financial results for the quarter ended June 30, 2026, alongside operational updates that underscore progress in its RedTail virotherapy platform. The company received positive pre-IND feedback f...
Delistings and Listing ChangesShareholder MeetingsStock Split
Calidi Biotherapeutics Implements Reverse Stock Split on NYSE
Neutral
Jul 31, 2026
On June 12, 2026, Calidi Biotherapeutics stockholders approved a 1-for-16 reverse stock split of the company’s issued and outstanding common stock. The measure was implemented as a proactive step to raise the per-share trading price and supp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.